Introduction
Patients who have either failed curative therapy such as radical prostatectomy or radiotherapy can be satisfactorily treated for progressively longer periods with adequate hormonal manipulations. With the mounting evidence that early hormonal therapy is better than delayed hormonal therapy, a large number of patients with relatively small volume disease will be controlled for periods of between 5 and 10 y before ultimately they develop a cancer which is resistant to hormonal manipulations and is often described as hormone-independent. 1 ± 3 The nucleus of the cancer that eventually will overcome the patient has probably been present from the origin of clinically detectable cancer and therefore, instead of reserving the various and sometimes toxic therapies used to treat hormone-independent cancer until the patient's general condition is so poor that he cannot tolerate them, it would seem logical that some of these therapies could be used early in the disease with good effect. 4 Possible therapeutic options for the treatment of hormone-independent prostatic cancer cells
The development of a tumour which is largely hormoneindependent is not a one-step process. As was described at the recent WHO Consensus Conference in Sweden in 1998, a prostate cancer goes through at least four stages before it is exclusively composed of hormone-independent cells. These stages are summarized in Table 1 . 5 Throughout the development of prostate cancer the hormonal treatments will be only affecting the amplifying cells and the secretory cells, and probably having very little effect on stem cells. The stem cells remain largely hormone-independent and, unless they are eliminated at the same time as the differentiated cells, the cancer will continue to grow. This mechanism is shown in Figure 1 .
In the last few years promising new compounds appeared with novel therapeutic effects which require novel strategies for their investigation and open up interesting new possibilities for combination therapy in the different stages of the cancer.
Cytotoxic options Estracyt
In 1979 Konvyers working with LEO Pharmaceuticals in Sweden developed a combination of oestrogen with a nornitrogen mustard which seemed to be particularly effective in poorly differentiated tumours. The use of this compound has been bedevilled by serious side effects caused by escalating the dose without suitable prophylaxis for possible gastrointestinal side effects instead of starting with a high dose and reducing it when the tumour is under control. Although the use of estracyt after previous hormonal therapies has only given rise to an objective response rate of 5%, in a recent metanalysis, it still seems capable of achieving a subjective response in a large percentage of patients. With the use of H3 antagonists and gastrointestinal sedatives the side effects can be reasonably controlled. 6 
Estracyt combination therapies
Following the development of chemotherapeutic protocols in the Memorial Sloan Kettering Institute, where a series of studies have shown that a reduction of PSA by 50% following the use of chemotherapeutic agents in very advanced disease is now associated with improved survival, various combination regimes have shown more encouraging results. In particular a combination of estramustine with taxanes and etoposide has achieved complete responses in measurable hormone-escaped disease in over 30% of patients. These sorts of responses are very similar to those seen in the 1980s in studies of M-VAC chemotherapy in bladder cancer and for the ®rst time suggest that there are effective hormone chemotherapeutic combination therapies in prostate cancer. 7, 8 Other chemo-hormonal therapeutic regimes
Recent evidence presented at the American Urological Association Meeting in Atlanta suggests that a combination of ketaconazole with hydrocortisone Hormone-independent prostate cancer DWW Newling biphosphonates may be capable of exerting a cytotoxic in¯uence on advanced prostate cancer. 9 
Systemic radiotherapy
Recent studies have suggested that the use of strontium 89 and possibly rhenium 163 combined with maximal androgen blockade can improve the response of hormone-naive metastatic prostate cancer patients. There is some experimental evidence that strontium 89 and rhenium 163 can affect not only boney metastases but also soft tissue metastases in animal models of hormone-naive metastatic disease. This may represent a disturbance of calcium metabolism by competitive ionic inhibition which prevents the high intracellular calcium levels necessary for the development of invasive potential. 10, 11 Immunotherapy gene therapy
As has been shown in both kidney cancer and bladder cancer, the use of immunotherapy is most effective when a tumour mass is small. There are various approaches which are still largely experimental in prostate cancer but which show promise particularly in the treatment of small volume disease. The use of herpes virus tyrosine kinase gene-therapy combined with ganciclovir or vanciclovir has been shown to be effective in the management of recurrent disease after radical prostatectomy. In a recent phase II in patients with hormone relapsed prostatic cancer, signi®cant reductions in PSA levels using this therapy have been found. 12 The development of vaccines including antibodies to PMSA have been demonstrated as safe in phase I and phase II studies against hormone refractory prostate cancer. 13 The use of other immunostimulatory techniques such as the production of granulocyte colony stimulating factor from transduced cells have also shown promise in phase I studies. There is encouraging experimental evidence that the introduction of antisense oligo nucleotides combined with cytokine therapy cause necrosis in prostate cancers prior to radical prostatectomy. The development of vaccines against prostate cancer combined with cytokine therapy is in an experimental stage and has yet to be launched in a phase I study. 14 
Biphosphonates
Although the use of biphosphonates in the past has been mainly restricted to the treatment of painful boney metastases, there is some recent evidence that, combined with differentiation therapy and hormonal therapy, ie ketokonazole and prednisone, that these agents may also have some preventative in¯uence on the development of boney metastases and phase III studies are being designed to test this effect both objectively and in terms of improvement of quality of life in hormone-relapsed prostatic cancer.
Biophosphonates may also be of use in preventing the complications of osteoporosis which occurs in the vast majority of patients with castrate levels of testosterone within 5 y. There is no doubt they still have an important role to play in the symptomatic treatment of painful boney metastases in patients with far advanced disease. 15 
Antiinvasive antiangiogenesis treatments
Inhibitors of matrix metallo proteinases, enzymes responsible for disrupting the extracellular matrix of tissues, have been used successfully in phase II studies in patients with far advanced disease and seem to be minimally toxic. Agents such as marimastat, AG3340 and BAI 12-9566 are orally administered compounds which would seem to be suitable for long-term administration without the need for regular monitoring. Marimastat has been used in the treatment of hormone-refractory prostate cancer and in a phase II study showed some bene®t in terms of PSA response. Further studies of this and other agents will be carried out in a phase III form in patients presenting with rising PSA after surgery or radiotherapy. The MMP inhibitors probably also have an effect on angiogenesis. Other angiogenesis agents such as linomide, thalinomide and antibodies to VEGF are in a very early state of development in the treatment of prostate cancer. 16 
Differentiation therapies
The use of retinoids and imidazoles to increase differentiation of poorly differentiated prostate cancer cells has been shown in cell culture to be an effective strategy. The initial imidazole employed clinically, ketoconazol, proved to be highly toxic and could only be used in therapeutic doses accompanied by hydrocortisone. Of the second generation imidazole derivatives, liarozole has been shown to be more effective than CPA as second line therapy in advanced prostate cancer, but was accompanied by very signi®cant side effects. 17 Further development with these compounds is underway and they will almost certainly ®nd a place in prostate cancer. Other differentiation agents such as phenylbutyrate and aromatic fatty acid, which are well absorbed orally, have been shown to have a signi®cant effect in prostate cancer cell lines and to be well tolerated in phase I studies. 18 One of the major disadvantages of differentiation therapy is the variable effect that it can have on PSA levels. Because they improve differentiation of cells, the PSA production may paradoxically be increased while the cell proliferation is reduced. 19 
Cytostatic agents
One advantage of cytostatic agents is that they tend not to have signi®cant effects on bone marrow proliferation while inhibiting proliferation of malignant cells. Vitamin D analogues, suramine and other growth factor inhibitors Hormone-independent prostate cancer DWW Newling including EGF, and ILGE receptor antagonists and fudothelin I are an interesting group of compounds which could well ®nd a place in the treatment of prostate cancer. A recent study of suramin and hydrocortisone was not accepted by the FDA in view of the marginal bene®t weighed against the signi®cant toxicity. Nevertheless, these compounds, particularly suramin, may well be used intermittently in combination with other therapeutic options in the future. 20 The investigation of new non-hormonal treatments in prostate cancer
After showing effectivity in cell lines and animal experiments the new agents may be tested in a variety of clinical situations, some of which may indicate the eventual role for the new compound.
Organ-con®ned disease
All new agents can be effectively investigated in patients prior to radical prostatectomy. The radical prostatectomy specimen can be examined and compared with the prostate biopsy specimen looking for evidence of apoptosis, diminution in proliferation indices and reduction in mitosis. With the establishment of molecular markers such as KI 67, P27, P12, and P53 expression a putative bene®cial effect can be seen when an agent is given systemically or injected directly into the prostate. This latter technique has been of particular interest in the development of immunotherapeutic and gene transfection studies. When a de®nitive treatment is to be radiotherapy, a new agent may also be tried with sequential biopsies before the administration of the agent and after its administration prior to radiotherapy. 21 
Rising PSA after de®nitive therapy
Treatment with cytotoxic therapies or new hormonal therapies can be tried in this stage of the disease. They will have an effect on the rising PSA and a useful parameter of the effect may be a comparison of the time to a second PSA progression in patients treated with the experimental therapy or with a standard hormonal manipulation.
Asymptomatic disease and a rising PSA after primary hormonal therapy
In these patients testing of new agents might be most quickly carried out by assessing the effect of these agents on the development of new metastases. When a patient presents with a rising PSA after primary therapy, without objective evidence of new tumour, new agents may be given and tested against placebo or second-line hormonal therapy with time to the development of objective metastases as an endpoint. As was shown in 1993, there is a lapse period, particularly in patients with small volume metastatic disease, after the initial rise in PSA, before a second rise occurs or objective evidence of new disease is found.
After all hormonal therapies have been used
In the classical situation a number of new agents have been tried in patients with far advanced disease with measurable soft tissue metastases. These patients have a very restricted duration of survival and are very often not in a suitable clinical state to receive aggressive cytotoxic therapy. The use of less toxic therapies such as cytostatic therapies or differentiation therapies may be most appropriate. It is most unlikely that these agents will have a signi®cant effect on survival in this group of patients and therefore the endpoint in these studies should probably be qualify of life. As was recently shown by Tannock et al, this is a useful parameter in these patients and has led to the acceptance of the combination of mythoxantrone and prednisone for use in hormone-refractory prostate cancer where quality and not quantity of survival has been improved.
Present strategies for the employment of non-hormonal therapies in prostate cancer Prophylaxis
In patients at high risk of developing prostate cancer or where PIN was found in prostatectomy tissue removed because of BPH there would seem to be justi®cation for advising patients on dietary changes including the use of vitamin E, vitamin A, reduction of fat intake and supplements such as selenium. Recent evidence too would suggest that it would be advisable in patients who are taking non-steroidal anti-in¯ammatory drugs, that the intake is modi®ed or stopped all together. The use of herbal remedies, particularly those containing geneitisin, has been shown to have inhibitory effects on prostate cancer cell lines and would certainly be worth suggesting. This group of patients may also be suitable for the use of gene and vaccine therapy prior to surgical ablation.
Locally advanced disease
The disappointing results of radical surgery and radiotherapy used as monotherapy in younger patients with poorly differentiated tumour, Gleason score 8 or over, and a high PSA, has led to the recent introduction of highdose combination chemotherapy and hormonal therapy as adjuncts to radical surgery or radiotherapy. The combination therapy of estramustine, taxanes and etoposide, together with maximal androgen blockade has been shown to reduce the PSA velocity following radical surgery or radiotherapy. The patient's general condition is usually good and therefore he is able to tolerate this aggressive therapeutic approach.
Asymptomatic metastatic disease
The prevention of complications of metastatic prostate cancer by the early administration of hormonal therapies has been established in a recent MRC study. The side effects of long-term continuous hormonal therapy are considerable. To reduce these and possibly also to postpone the development of clones of totally hormone-resistant cells, Buchovsky et al introduced the concept of intermittent therapy. As a progression of this idea it would seem appropriate to consider the use of other therapies during a period when a patient is no longer receiving endocrine manipulation. Because one of the advantages of intermittent therapy is an improvement of the patients quality of life during the period of therapy, it would be dif®cult to persuade these patients to accept aggressive cytotoxic therapy in the intervening periods. What might be appropriate, however, would be the use of cytostatic therapies or differentiation therapies which could inhibit proliferation of the stem cells and therefore further inhibit the differentiation process which will go on when hormone therapy is discontinued. The confounding in¯uence of differentiation agents on PSA expression may limit their usefulness in this group of patients where a rising PSA will be the indication for resumption of endocrine therapy.
Treatment of symptomatic metastatic prostate cancer
The EORTC and other organisations have experimented in the past with the combination of maximal androgen blockade or castration conventional cytotoxic agents. They have not been shown in this group of patients to be a particularly useful combination. Indeed in the EORTC study the toxicity was such that many patients were unable to continue with Mitomycine C, the cytotoxic used. 22 With the development of more effective cytotoxic therapies, such as estramustine combined with taxanes and etoposide, this renewal is of interest in investigating multimodal therapy for patients presenting with symptomatic metastatic disease. Again, the general condition of the patient might limit the exposure to cytotoxic agents in view of diminishing bone marrow reserves. There may, however, be a place for combinations of hormone and cytostatic agents or hormones combined with differentiation agents where bone marrow reserves are severely depleted.
True hormone-refractory prostate cancer
Where all hormonal therapies have been already applied, the palliative effect of the less toxic non-hormonal manipulations may be of considerable use. While unlikely to improve the survival of these patients, a number of the above described strategies may give symptomatic relief and improvement in the patient's quality of life.
Conclusions
A better understanding of prostate cancer and particularly the mechanism of the development of its invasive potential and metastatic spread has led to a more structured investigation of non hormonal therapies and to the development of potentially exciting new treatment strategies. It is important that all new treatment modalities are investigated in a logical and reproducible way and that surrogate endpoints such as PSA progression and the investigation of molecular markers are being employed to accelerate the adoption of useful new therapies. The existence of potentially hormone refractory cells from the beginning of the life of a prostate cancer, indicates that for cure to be possible in those patients where radical prostatectomy or radiotherapy will not guarantee a tumour-free state, non-hormonal therapies directed as stem cells and possible other cells such as neuroendocrine cells which remain hormone-insensitive, should be started at an early stage.
